NICE Appraisal of Alzheimer's Drugs, UK

Speaking about press coverage of the Institute's technology appraisal on the use of donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer's disease, NICE Chief Executive Andrew Dillon stated: "The Institute would like to make it clear that contrary to recent press reports it has not been asked or told by Ministers to reverse its advisory committee's provisional recommendations on the use of these drugs. Consultation on the provisional recommendations will continue until 22 March and anyone with an interest in the appraisal can comment via our web site. The advisory committee will meet in June to consider the responses received and will prepare final advice shortly afterwards."

Medical News Today (http://www.medicalnewstoday.com/medicalnews.php?newsid=21286&nfid=rssfeeds)